单纯化疗与化疗联合靶向药物对晚期胆道系统肿瘤的疗效比较的Meta分析

doi:10.3969/j.issn.1671-7171.2018.10.008

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To evaluate the role of chemotherapy and targeted drug treatment in advanced biliary tract cancer (BTC). 【Methods】By searching MEDLINE, EMBASE and other domestic and foreign databases, a randomized controlled trial (RCT) for advanced BTC was conducted. The patients in the observation group were treated with chemotherapy combined with targeted drugs, while the patients in the control group received chemotherapy alone. Meta analysis on the objectiv remission rates, median overall survival (OS), progression free survival (PFS), and adverse events was performed in both groups. 【Results】A total of 8 RCTs were enrolled, including 1052 patients in total. There were 549 patients in the observation group and 503 patients in the control group. The objective remission rate in the observation group was significantly higher than that in the control group (P<0.05). However, there were no significant differences in OS, the first half year of PFS and one year PFS between the two groups (P>0.05). The incidence of nausea / vomiting and bone marrow toxicity was not significantly different between the two groups (P>0.05). The incidence of skin toxicity and diarrhea in the observation group was higher than that in the control group (P<0.05). 【Conclusion】Based on the latest RCTs, meta-analysis shows that chemotherapy combined with targeted therapy can improve the objective response rate of late BTC. However, it does not have significant survival benefits.

Key words： Biliary Tract Neoplasms Chemotherapy, Adjuvant Meta-Analysis

Received: 24 October 2016

PACS:

R735.8

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Xiao-hua
	LIAO Jia
	YANG Fan
	et al

Cite this article:

WANG Xiao-hua,LIAO Jia,YANG Fan, et al. Meta-analysis of the Efficacy of Chemotherapy Alone vs. Chemotherapy Combined with Targeted Drugs for Advanced Biliary Tract Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(10): 1895-1898.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2018.10.008 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2018/V35/I10/1895

[1] Moriwaki T, Yamamoto Y, Gosho M,et al.Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy[J].Br J Cancer,2016 12;114(8):881-888.
[2] Eckel F, Schmid RM. Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials[J].Chemotherapy,2014;60(1):13-23.
[3] Vogel A, Kasper S, Weichert W, et al. Panitumumab in combination with gemcitabine /cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase Ⅱ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)[J].J Clin Oncol,2015, 33(2) :4082.
[4] Chen JS, Hsu C, Chiang NJ, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer[J].Ann Oncol,2015,26(5):943-949.
[5] Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial[J].Lancet Oncol,2015,16(8):967-978.
[6] Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)[J].Cancer,2016,122(4):574-581.
[7] Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial[J].Lancet Oncol,2014,15(8):819-828.
[8] Moehler M, Maderer A, Schimanski C,et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase Ⅱ AIO study with biomarker and serum programme[J].Eur J Cancer,2014,50(18):3125-3135.
[9] Lee J, Park SH, Chang HM,et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study[J].Lancet Oncol,2012,13(2):181-188.
[10] Santoro A, Gebbia V, Pressiani T, et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study[J].Ann Oncol,2015,26(3):542-547.